zurück

Tixagevimab / cilgavimab (obligation for benefit assessment for the first time: COVID-19; patients not requiring supplemental oxygen; patients aged ≥ 12 years)

 

Subject:

  • Active Substance: Tixagevimab / cilgavimab
  • Name: Evusheld®
  • Therapeutic area: Coronavirus disease 2019 (COVID-19)
  • Pharmaceutical company: AstraZeneca GmbH

 

Time table:

  • Start: 15.10.2022
  • Publication of assessment: 16.01.2023
  • End of public hearing: 06.02.2023
  • Final decision by G-BA: beginning of April 2023

 

Comparative therapy:

  • Therapy at the physician's discretion